Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
Numerous investigators have shown that the glycoprotein IIb/IIIa integrin mediates the final common pathway in platelet aggregation which has led to development of GP IIb/IIIa receptor antagonists. This article reviews the current status of GP IIb/IIIa receptor blockade in the management of coronary artery disease, examining the results of pivotal clinical trials.